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Abstract
Background: Aldo-keto reductase (AKR) 1C family member 3 (AKR1C3), one of four identified human AKR1C
enzymes, catalyzes steroid, prostaglandin, and xenobiotic metabolism. In the prostate, AKR1C3 is up-regulated in
localized and advanced prostate adenocarcinoma, and is associated with prostate cancer (PCa) aggressiveness.
Here we propose a novel pathological function of AKR1C3 in tumor angiogenesis and its potential role in
promoting PCa progression.
Methods: To recapitulate elevated AKR1C3 expression in cancerous prostate, the human PCa PC-3 cell line was
stably transfected with an AKR1C3 expression construct to establish PC3-AKR1C3 transfectants. Microarray and
bioinformatics analysis were performed to identify AKR1C3-mediated pathways of activation and their potential
biological consequences in PC-3 cells. Western blot analysis, reverse transcription-polymerase chain reaction (RT-
PCR), enzyme-linked immunosorbent assay (ELISA), and an in vitro Matrigel angiogenesis assays were applied to
validate the pro-angiogenic activity of PC3-AKR1C3 transfectants identified by bioinformatics analysis.
Results: Microarray and bioinformatics analysis suggested that overexpression of AKR1C3 in PC-3 cells modulates
estrogen and androgen metabolism, activates insulin-like growth factor (IGF)-1 and Akt signaling pathways, as well
as promotes tumor angiogenesis and aggressiveness. Levels of IGF-1 receptor (IGF-1R) and Akt activation as well as
vascular endothelial growth factor (VEGF) expression and secretion were significantly elevated in PC3-AKR1C3
transfectants in comparison to PC3-mock transfectants. PC3-AKR1C3 transfectants also promoted endothelial cell
(EC) tube formation on Matrigel as compared to the AKR1C3-negative parental PC-3 cells and PC3-mock
transfectants. Pre-treatment of PC3-AKR1C3 transfectants with a selective IGF-1R kinase inhibitor (AG1024) or a non-
selective phosphoinositide 3-kinases (PI3K) inhibitor (LY294002) abolished ability of the cells to promote EC tube
formation.
Conclusions: Bioinformatics analysis followed by functional genomics demonstrated that AKR1C3 overexpression
promotes angiogenesis and aggressiveness of PC-3 cells. These results also suggest that AKR1C3-mediated tumor
angiogenesis is regulated by estrogen and androgen metabolism with subsequent IGF-1R and Akt activation
followed by VEGF expression in PCa cells.
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T h ea l d o - k e t or e d u c t a s e( A K R )e n z y m e sc o m p r i s ea
functionally diverse gene family [1]. Members of the
AKR superfamily are generally monomeric (37 kD) cyto-
solic NAD(P)(H)-dependent oxidoreductases that con-
vert carbonyl groups to primary or secondary alcohols,
a n ds h a r eac o m m o n( a/b)8-barrel structural motif
(visit: http://www.med.upenn.edu/akr) [2]. In humans,
four AKR1C isoforms have been identified; they are
known as AKR1C1 [20a(3a)-hydroxysteroid dehydro-
genase (HSD)] [3], AKR1C2 (type 3 3a-HSD) [4,5],
AKR1C3 (type 2 3a/type 5 17b-HSD) [6,7], and
AKR1C4 (type 1 3a-HSD) [5]. Natural substrates for
these enzymes include steroids [8,9], prostaglandins
[10], and lipid aldehydes [11].
Originally cloned from human prostate [7] and pla-
cental cDNA libraries [12], AKR1C3 shares greater than
86% sequence identity with the other three highly
related human AKR1Cs [13]. AKR1C3 catalyzes both
androgen and estrogen metabolism. The relatively high
17b-HSD activity of this enzyme reduces Δ
4-androstene-
3,17-dione (Δ
4-dione; a weak androgen) to yield testos-
terone (a potent androgen) [14], and reduces estrone (a
weak estrogen) to yield 17b-estradiol (a potent estrogen)
[13]. Using its 3a-HSD activity, AKR1C3 reduces 5a-
dihydrotesterone (5a-DHT, a potent androgen) to 5a-
androstane-3a,17b-diol (3a-diol, a weak androgen) [7].
As a result, AKR1C3 may be capable of modulating the
amounts of potent androgen (testosterone and 5a-DHT)
and estrogen (17b-estradiol) available for the androgen
receptor (AR) and estrogen receptor (ER), respectively.
Deregulated AKR1C3 expression has been associated
with multiple human cancers. Suppressed AKR1C3
expression has been demonstrated in breast cancer [15]
and endometrial cancer [16], whereas elevated expres-
sion of this enzyme has been reported in squamous cell
carcinoma of the head and neck [17]. In the prostate,
low or undetectable levels of AKR1C3 are observed in
normal prostate epithelium [18], whereas levels of
AKR1C3 expression are significantly elevated in loca-
lized [19,20], advanced [21], and recurrent [22] prostate
cancer (PCa).
Based on the observations that expression of AKR1C3
is elevated in both localized and metastatic PCa, the
enzyme might modulate significant pathological activ-
ities in cancer development or progression. Studies so
far have been focused on the potential androgenic
effects mediated by AKR1C3 in the prostate; and ele-
vated AKR1C3 expression in the prostate is thought to
be responsible for testosterone and 5a-DHT accumula-
tion and AR trans-activation in cancerous prostate
[14,20,21]. In this report, an androgen insensitive, AR-
negative human PCa PC-3 cell line was stably trans-
fected with AKR1C3 cDNA to establish PC3-AKR1C3
transfectants and to recapitulate elevated expression of
this enzyme in PCa. Microarray, bioinformatics, and lit-
erature analyses were used to explore possible pathologi-
cal consequences of elevated AKR1C3 expression in PCa
cells. In addition to elevated cell growth in PC3-
AKR1C3 transfectants [23], AKR1C3 overexpression
promoted angiogenic capability of PC-3 cells as evi-
denced by elevated levels of vascular endothelial growth
factor (VEGF) expression and PC-3 cell-mediated
endothelial cell (EC) tube formation on Matrigel. These
results suggest that, AKR1C3-mediated steroid hor-
mones or prostaglandin metabolism may promote
aggressiveness of PCa through enhanced tumor
angiogenesis.
Methods
Reagents and chemicals
PC-3 cells (CRL-1435) derived from a human bone
metastatic tumor and LNCaP-FGC (LNCaP) cells (CRL-
1740) were obtained from ATCC (Manassas, VA). An
SV40 large T-antigen transformed human microvascular
EC line, HMEC-1 [24], was generously provided by Dr.
Michael Ihnat at the University of Oklahoma Health
Sciences Center. RPMI 1640 medium, F-12 nutrient
mix, MCDB 131 medium, penicillin-streptomycin, fetal
bovine serum (FBS), pcDNA3 vector, Trizol, and
Lipofectamine 2000 were purchased from Invitrogen
(Carlsbad, CA). AG1042 and LY294002 were purchased
from EMD Chemicals (Gibbstown, NJ). Matrigel
basement membrane matrix was purchased from BD
Biosciences (Bedford, MA). Mouse anti-AKR1C3 mono-
clonal antibody was produced in our laboratories [25].
Rabbit anti-insulin-like growth factor (IGF)-1 receptor
(IGF-1R) b, rabbit anti-phospho-IGF-1R b (Tyr 1131),
rabbit anti-Akt, and rabbit anti-phospho-Akt (Ser 473)
polyclonal antibodies, as well as horseradish peroxidase
(HRP)-linked goat anti-rabbit IgG were obtained
from Cell Signaling Technology (Danvers, MA). Mouse
anti-human b-actin antibody was obtained from Sigma-
A l d r i c h( S t .L o u i s ,M O ) .H R P - c o n j u g a t e dg o a ta n t i -
mouse IgG was obtained from KPL (Gaithersburg, MD).
Bicinchoninic acid (BCA) protein assay kit and
enhanced chemiluminescent (ECL) substrate reagent
were obtained from Pierce (Rockford, IL). VEGF
enzyme-linked immunosorbe n ta s s a y( E L I S A )k i tw a s
purchased from Ray Biotech (Norcross, GA).
Prostate cell culture and transfection
PC-3 cells were cultured in complete growth medium
consisting of F-12 nutrient mixture, 7% FBS, and 100
units/ml penicillin-100 µg/ml streptomycin. LNCaP cells
were cultured in complete growth medium consisting of
RPMI-1640, 10% FBS, and penicillin-streptomycin.
HMEC-1 were maintained in MCDB 131 medium
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All cells were maintained in a humidified cell incubator
at 37°C and 5% CO2. AKR1C3 expression construct
(pcDNA3-AKR1C3) was established as previously
described [23]. Transfection of PC-3 cells with either
pcDNA3 empty vector or pcDNA3-AKR1C3 construct
was achieved using Lipofectamine 2000. Stable transfec-
tants were established in the presence of 600 μg/ml G418
selection. PC-3 stable transfectants were designated as
PC3-mock or PC3-AKR1C3 for cells transfected with
pcDNA3 or pcDNA3-AKR1C3 plasmid, respectively.
Multiple independent clones were isolated and expanded
i nt h ec o m p l e t eg r o w t hm e d ium containing G418. PC3-
AKR1C3 clones were confirmed with elevated AKR1C3
mRNA and protein expression as compared to parental
PC-3 cells and PC3-mock transfectants. LNCaP-mock
and LNCaP-AKR1C3 stable transfectants were also simi-
larly established.
RNA extraction and quality evaluation
Total RNA was isolated from 2 independent PC3-mock
clones and 3 independent PC3-AKR1C3 clones for a
comprehensive gene expression analysis using oligonu-
cleotide arrays. Briefly, following PC-3 transfectants (5 ×
10
5) seeding and adherence, total RNA was isolated
from these clones using Trizol followed by RNeasy®
Mini total RNA isolation kit (Qiagen, Valencia, CA)
purification. Concentration of the isolated total RNA
was determined with a Nanodrop scanning spectrophot-
ometer; and quality of the total RNA was assessed using
the ratio of 28:18 s rRNA by Agilent 2100 Bioanalyzer
capillary gel electrophoresis system (Agilent Technolo-
gies, Santa Clara, CA).
RNA labeling, microarray hybridization, and scanning
A total of 250 ng total RNA from each clone was
labeled using the Illumina Total Prep RNA Amplifica-
t i o nk i t( A m b i o n ,A u s t i n , .T X ) .B r i e f l y ,c D N Aw a s
reverse transcribed from the total RNA after priming
with T7-oligo(dT); and cRNA was synthesized from the
T7 promoter in the presence of biotinylated UTP. Bioti-
nylated cRNA was hybridized to Illumina HumanWG 6
v2 BeadChips containing a total of 48,702 probes (Illu-
mina Inc., San Diego, CA). Hybridization was detected
by incubating the microarray chips with streptavidin-
Cy3 (Amersham Biosciences, Piscataway, NJ) and
scanned on an Illumina BeadArray Reader.
Data normalization and identification of AKR1C3
regulated genes
Raw expression values were first normalized based on a
normal distribution of genes with low expression levels
as previously described [26,2 7 ] .B r i e f l y ,n o r m a l i z a t i o n
was performed for each array by first plotting a
frequency histogram of the raw expression data for all
genes. The histograms showed a right-skewed unimodal
distribution curve with the mode around zero. A normal
distribution curve representing random variability of the
genes with low expression values was then fitted around
the mode, mirroring Gaussian profile of the left part of
the histogram. Two parameters [mean and standard
deviation (SD)] were defined. The expression values
then were normalized to the SD of the normal
distribution after subtraction of the mean and then log10-
transformed. The arrays were than adjusted to each other
by robust linear regression [28,29]. Genes with expres-
sion values less than 3.0 (or 0.477 in log10 scale) were
considered to be not expressed; this is equivalent of
setting a threshold at 3 SD above noise level. Raw and
normalized gene expression data are available on Gene
Expression Omnibus (GEO accession GSE20956).
To identify genes that are differentially expressed
between PC3-mock and PC3-AKR1C3 transfectants, an
associative analysis was performed as described by Doz-
morov et al. [30]. Briefly, in combined microarray data-
sets from both PC3-mock and PC3-AKR1C3
transfectants, a reference group of genes expressed
above background with low variability of expression as
compared with variability of all others was identified by
a F-test. The variability in expression of these genes was
assumed to represent the technical variability of the
assay. Associative t-test (the standard t-test applied to
the comparison of expression variability) was used to
test the null hypothesis if a given gene under a given
condition is associated with the reference group. Those
with statistically significant variability over the reference
set were assumed to represent variability due to the bio-
logical variables being manipulated.
An additional analysis was performed to minimize
threshold choice effects in different statistical
approaches in microarray data analysis [31]. Class com-
parison between PC3-mock and PC3-AKR1C3 transfec-
tants was performed using the BRB ArrayTools. To use
the BRB Array Tools, raw expression values were log2
transformed; and quantile normalization was applied.
Differentially expressed genes between the two classes,
PC3-mock and PC3-AKR1C3 transfectants, were identi-
fied by random-variance t-test. The random-variance
t-test, implemented in the BRB ArrayTools, is an
improvement of the standard t-test since it permits
sharing information among genes with within-class var-
iation, without assuming that all genes have the same
variance [32]. A stringent significance threshold was
applied to limit the number of false positive findings;
genes were considered statistically significant if their
P-values were less than 0.001. Lists of differentially
expressed genes from associative t-test and class com-
parison analysis were compared; and genes identified by
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otherwise stated.
Functional analysis and identification of canonical
pathways
For pathway analysis of the microarray data, gene lists
were analyzed by Ingenuity Pathway Analysis (IPA; Inge-
nuity® Systems, Redwood City, CA, http://www.ingenu-
ity.com), a web-based bioinformatics tool. Each gene list
was tested against the full Illumina HumanWG 6 v2
dataset to identify significantly overrepresented func-
tions and canonical pathways as compared to the same
number of randomly selected genes. The most signifi-
cant functions and canonical pathways with P <0 . 0 5
were selected; and genes overrepresented in the func-
tions and pathways were identified. The branches of
pathways containing genes that are not expressed on
microarrays were not considered functional.
Analysis of 5’-flanking regions of the differentially
expressed genes
To explore transcriptional regulatory mechanisms of the
genes regulated in PC3-AKR1C3 versus PC3-mock
transfectants, the promoter analysis and interaction net-
work toolset (PAINT) http://www.dbi.tju.edu/dbi/tools/
paint/) [33] was used to identify overrepresented cis-act-
ing elements, or transcription factor binding sites, within
the identified genes against the same transcription regu-
latory elements (TREs) selected randomly from the
whole set of genes on the microarray. Statistical signifi-
cance for testing the presence of TREs was set at P <
0.05; and additional filtering was performed by using a
false discovery rate (FDR) as described in the text.
Data validation by literature analysis
Literature-based matching of genes to concepts provides
an advantage over gene ontology (GO) enrichment analy-
sis in that first, GO annotation lags literature publica-
tions, and second, more importantly it provides a much
broader matching of genes to concepts, such as diseases,
phenotypes, chemical compounds, and other genes fre-
quently associated with the gene set being analyzed. To
perform literature analysis, lists of differentially expressed
genes between PC3-mock and PC3-AKR1C3 transfec-
tants were analyzed by a comprehensive, computational
search of published MEDLINE abstracts via as o f t w a r e
package called IRIDESCENT [34-36]. There were 7 and
39 up- and down-regulated genes in PC3-AKR1C3 trans-
fectants, respectively, not mentioned in the literature and
were automatically discarded, since, by definition, they
could not share any literature-based commonalities with
other genes. This left 56 up-regulated and 108 down-
regulated genes available for analysis. IRIDESCENT uses
a thesaurus of names and their synonyms obtained from
public databases such as OMIM, Entrez Gene, GO, CHE-
MID, and Disease Ontology to recognize these “objects”
and their common spelling variants (e.g., “IL2” and “IL-
2”) within text. All available MEDLINE records (approxi-
mately 18 million at the time of this writing) were pro-
cessed to identify “objects” co-occurring within the same
abstracts, and within the same sentences within those
abstracts. The number of co-occurrences was tallied,
with a weighting based on a previous study [35] of 0.5 for
objects co-mentioned in the same abstract and 0.8 for
objects co-mentioned in the same sentence, providing a
network of terms connected by their relative strength of
association. Once commonalities had been identified in
the literature for a gene set, each was compared to an
identically connected set within a random network
model to calculate a ratio of how many connections were
observed in the actual dataset versus how many connec-
tions would be expected by chance (Obs/Exp ratio), pro-
viding a measure of statistical enrichment for each term.
The significance of enrichment was calculated using a
Monte Carlo simulation and the associations reported
were ≥ 3 SDs from the mean (P ≤ 0.01).
Western blot analysis
Western blot analysis was performed to confirm IGF-1R
and Akt activation in PC3-AKR1C3 transfectants identi-
fied by bioinformatics analysis. Briefly, following cell
(1 × 10
6) seeding and adherence, PC3-mock and PC3-
AKR1C3 transfectants were lysed with RIPA buffer
supplemented with 5 mM EDTA, 0.1 mM phenyl-
methylsulphonylfluoride (PMSF), Complete Mini-
Protease Inhibitor Cocktail, and PhosSTOP Phosphatase
Inhibitor Cocktail (Roche Applied Science, Indianapolis,
IN). Total cellular proteins were collected following cen-
trifugation to remove cellular components and quanti-
fied using the BCA protein assay kit. Aliquots (30 µg) of
the cellular proteins were separated on 10% Tris-HCl
gels; and separated proteins were transferred onto PVDF
membranes (Bio-Rad; Hercules, CA). The membranes
were incubated with rabbit anti-human phospho-IGF-1R
b (Tyr 1131) antibody (1:250), rabbit anti-human IGF-
1R b antibody (1:1,000), rabbit anti-human phospho-Akt
(Ser 473) antibody (1:250), or rabbit anti-human Akt
antibody (1:1,500) followed by HRP-conjugated goat
anti-rabbit IgG (1:2,000) incubation. Immunoreactive
proteins were detected using the ECL reagent. The
membranes were then stripped and incubated with a
mouse anti-human b-actin monoclonal antibody
(1:5,000) followed by HRP-conjugated goat anti-mouse
IgG (1:10,000) incubation and ECL development.
Quantification of VEGF expression
VEGF appears to be one of the most important factors
released by tumor cells as a signal for angiogenesis.
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AKR1C3 and PC3-mock transfectants. Levels of VEGF
mRNA expression were determined in these transfec-
tants using semi-quantitative reverse transcription-poly-
merase chain reaction (RT-PCR) method. Total RNA
isolation, first-strand cDNA synthesis, PCR amplification
using pre-designed VEGF isoform-specific primer pairs
and pre-determined cycling conditions followed our
reported procedures [37]. PCR amplified products were
separated on 1% agarose gels and stained with ethidium
bromide. Images of ethidium bromide-stained gels were
acquired with Gel Doc 1000 (Bio-Rad) equipped with
Quantity One® imaging software (Bio-Rad). The involve-
ment of IGF-1R and phosphoinositide 3-kinases (PI3K)
in VEGF mRNA expression in PC3-AKR1C3 transfec-
tants was studied by adding 20 µM AG1024 (IGF-1R
selective tyrosine kinase inhibitor) and 10 µM LY294002
(non-selective PI3K inhibitor), respectively, to the cell
cultures at 2 hours prior to total RNA isolation. The
selected concentrations of AG1024 and LY294002 did
not interfere with cell viability as determined by XTT
assay (data not shown).
Total VEGF secretion by PC3-mock and PC3-AKR1C3
C1 transfectants was quantified in conditioned media
using a RayBio® human VEGF ELISA kit following the
manufacture’s recommendations. Briefly, 1 × 10
6 cells
were seeded onto 60 mm cell culture plates in 2 ml
completed medium in duplicate. At 24 hours following
cell seeding, the conditioned media were removed and
centrifuged at 300 × g to clear cellular components. Ali-
quots (100 μl) of the conditioned media were transferred
to each well of the 96-well assay plate. Known quantities
of VEGF A165 were added in separate wells, run in par-
allel, and used to construct a standard curve. The plate
was read at 450 nm on a μQuant microplate reader
( B i o - T e kI n s t r u m e n t ,W i n o o s k i ,V T ) .R e s u l t sw e r en o r -
malized to total protein present in the media, as deter-
mined by the BCA assay, and reported as pg of total
secreted VEGF/μg total protein.
EC tube formation assay
An image-based, PCa cell-mediated EC tube formation
on Matrigel assay was used as an in vitro model to
assess enhanced angiogenic capability of PC3-AKR1C3
transfectants predicted by bioinformatics. Briefly, PC3-
mock and PC3-AKR1C3 transfectants (8 × 10
4) were re-
suspended in 0.25 ml liquid Matrigel and plated into
each well of 24-well tissue culture plates in duplicate.
Following overnight incubation, 8 × 10
4 HMEC-1 in
0.25 ml of the MCDB 131 complete medium were intro-
duced on top of the solidified PC-3 transfectant-Matri-
gel suspension. The co-cultures on Matrigel were
monitored and photographed at 6, 12, 24, 48, and 72
hours following HMEC-1 cell addition using an
Olympus IX51 inverted microscope equipped with
SPOT Insight CCD digital camera and SPOT Advance
software (Diagnostic Instruments, Sterling Heights, MI).
Three images were randomly taken from each well.
Images in JPEG format were uploaded into Image Pro-
Plus 6 (Media Cybernetics, Bethesda, MD), converted to
green on the RGB color channel to eliminate the red
color of Matrigel, and flattened. The number of tubes
was counted using the dendrite/tube template in the
Image Pro-Plus software; and non-tube forming cells
suspended on Matrigel were mathematically excluded
from counting [37]. The co-culture HMEC-1 tube for-
mation model was also applied to 2 clones of each from
LNCaP-mock and LNCaP-AKR1C3 transfectants.
To determine the roles of IGF-1R and PI3K in pros-
tate cell-mediated EC tube formation, parental PC-3
cells as well as PC3-mock and PC3-AKR1C3 transfec-
tants were first incubated with 20 µM AG1024 or
10 µM LY294002 at 37°C for 2 hours. Cells were then
harvested, washed with phosphate-buffered saline (PBS),
and suspended in Matrigel followed by HMEC-1 addi-
tion, image acquisition, and EC tube quantification
using the above described procedures.
Statistical analysis
Statistical differences between PC3-mock and PC3-
AKR1C3 stable transfectants were analyzed using stu-
dent t-test. Statistically significant difference was set
when P < 0.05.
Results
Identification of genes that are regulated by elevated
AKR1C3 expression in PC3-AKR1C3 transfectants
Gene expression profiles were compared between PC3-
mock and PC3-AKR1C3 transfectants using microarray
and bioinformatics techniques to predict possible altera-
tions of gene expression in AKR1C3-positive PCa.
When a threshold was set at 3 SDs above noise level,
approximately 12,000 genes were expressed above the
level in all arrays. The BRB ArrayTools class comparison
identified 70 genes being up-regulated and 153 genes
being down-regulated in PC3-AKR1C3 versus PC3-
mock transfectants. The associative analysis identified
27 genes being up-regulated and 85 genes being down-
regulated by at least 1.5 fold and expressed greater than
20 SDs above the noise levels in PC3-AKR1C3 versus
PC3-mock transfectants (Additional file 1). Class com-
parison and associative analysis provided almost overlap-
ping results. The 27 up-regulated genes identified by the
associative analysis were a subset of the 70 genes identi-
fied by the BRB ArrayTools. Among the 85 down-regu-
lated genes identified by the associative analysis, 76
genes were among the 153 genes identified by the BRB
ArrayTools (Additional file 2). The 27 up-regulated and
Dozmorov et al. BMC Cancer 2010, 10:672
http://www.biomedcentral.com/1471-2407/10/672
Page 5 of 1676 down-regulated genes in PC3-AKR1C3 transfectants
identified by both analyses were used as “beacon” genes
for further analysis to reduce the possibility of including
false positives. However, in some cases, the number of
“beacon” genes was insufficient to identify their com-
mon functions or other properties. Each “beacon” gene
may represent a unique function or feature, and the sta-
tistical calculations for overrepresentation of such fea-
tures become impossible. In such cases, the 70 up- and
153 down-regulated gene lists identified by the BRB
ArrayTools were used, as described in the text. The
inclusion of these genes was further validated by subse-
quent statistical analysis for overrepresentation of com-
mon features among genes in the lists.
AKR1C3 effects on steroid signaling in PC-3 cells
Genes that are differentially expressed in PC3-AKR1C3
versus PC3-mock transfectants were submitted to IPA to
predict pathways that are modulated by the AKR1C3-
regulated genes. Manual inspection of pathways and net-
works assembled by Ingenuity suggested that AKR1C3
affected genes in estrogen and, potentially, androgen sig-
naling pathways in PC-3 cells. A joint analysis of the 27
up- and 70 down-regulated genes ranked by ratios of
gene expression between PC3-mock and PC3-AKR1C3
transfectants identified networks of genes mainly cen-
tered by steroid metabolites, 17b-estradiol and 5a-DHT
(Figure 1A). For example, in the network of genes up-
regulated in PC3-AKR1C3 transfectants, the 5a-DHT
signal was linked directly to kallikrein-related peptidase
(KLK) 3 (prostate-specific antigen; PSA), TMPRSS2, and
indirectly to several other genes. The 17b-estrsdiol signal
was linked directly to HBEGF, KLK3, KLK5, FBLN1, and
WNT5B. In addition, 17b-estradiol was directly linked to
SERPIN5B, CDH11, and several other genes down-regu-
lated by the overexpression of AKR1C3 in PC-3 cells.
To predict the association between AKR1C3 and other
genes in published data, a global meta-analysis method
developed previously was used [38]. Analysis of a total
of 3,651 published microarray datasets identified probes
for AKR1C3 in 2,373 of them. Within these experi-
ments, AKR1C3 was co-expressed with many genes, but
A B
Figure 1 Influence of steroid hormone signaling in PC3-AKR1C3 transfectants. (A) Genes whose expression is altered in PC3-AKR1C3
transfectants were identified to be regulated by 17b-estradiol, androstenediol, or 5a-DHT. Genes that are labeled in red and green represent up-
and down-regulated genes, respectively, in PC3-AKR1C3 transfectants as compared to PC3-mock transfectants. The fold changes are reflected by
corresponding numbers under the gene names. (B) FST expression can be regulated by AKR1C3-mediated testosterone and/or progesterone
metabolism in PC3-AKR1C3 transfectants. The legend for the gene shapes is at lower right corner.
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positive correlation with AKR1C3 (Figure 1B). FST was
identified as one of significantly down-regulated genes
in PC3-AKR1C3 transfectants in our dataset (Additional
file 2). IPA indicated the interaction between AKR1C3
and FST may result from their interconnection with
progesterone and testosterone metabolism.
Activation of VDR/RXR and IGF-1 signaling pathways in
PC3-AKR1C3 transfectants
Functional classification predicted biological consequences
of the up-regulated genes in PC3-AKR1C3 transfectants.
Among the 27 genes up-regulated in PC3-AKR1C3 trans-
fectants, 4 genes were not present in the Ingenuity data-
base, 11 genes were poorly functionally annotated to be
eligible for statistical calculations, and only 12 genes were
eligible for functional classification. Ingenuity analysis
identified a group of 7 genes (BEX1, FBLN1, FGD3,
HBEGF, KLK3, KLK6, and WNT5B) related to cancer, cel-
lular function and maintenance, cellular growth, invasion,
as well as proliferation with P < 0.001-0.05 (Table 1).
Since IPA was not able to identify any significantly
overrepresented pathways based on the limited number
of genes, the 70-gene list identified by the BRB Array-
Tools analysis was submitted for pathway analysis. To
minimize false positives, these genes were first filtered
to select genes that have been identified in both human
and PC-3 cells. Among the 70 genes, 16 genes were eli-
gible for generating networks (Additional file 1). Using
the IPA tool, several overrepresented canonical pathways
were identified. VDR/RXR activation (P < 0.0001) was
overrepresented by cystatin E/M (CTS6), KLK6, and
protein kinase C, eta (PRKCH). The second most
significant pathway was IGF-1 signaling (P < 0.01; Figure
2A) represented by IGF binding protein 4 (IGFBP4) and
PRKCH. It was noticed that analysis of the 70-gene list
without filtering does not change the significance of the
identified canonical pathways, but added insulin recep-
tor substrate 2 (IRS2) to the IGF-1 signaling pathway.
Activation of IGF-1R and its downstream Akt signal-
ing molecule were confirmed by phosphorylated levels
of the respective proteins using Western blot analysis.
There was no difference in total IGF-1R and Akt expres-
sion between PC3-mock and PC3-AKR1C3 transfec-
tants, as also reflected by corresponding mRNA
expression on microarrays (data not shown). In contrast,
levels of phosphorylated IGF-1R b (Tyr 1131) and Akt
(Ser 473) expression were significantly elevated in all
PC3-AKR1C3 clones as compared to PC3-mock trans-
fectants or parental cells (Figure 2B).
Suppression of cell death genes and inactivation of the
p53 pathway in PC3-AKR1C3 transfectants
Genes whose expression were suppressed in PC3-
AKR1C3 versus PC3-mock transfectants were also sub-
jected to functional classification to predict biological
outcomes in PCa cells. Among the 76 genes down-regu-
l a t e di nP C 3 - A K R 1 C 3t r a n s f e c t a n t s ,2 4o ft h e mw e r e
not mapped in the Ingenuity database and 17 genes
were not sufficiently annotated to count in a statistical
calculation (Additional file 2). Among the remaining 35
genes eligible for functional c l a s s i f i c a t i o n ,1 5o ft h e m
were significantly overrepresented in the cell death func-
tional category with P < 0.0005 with 3 genes (ID1,
PMAIP1, and SERPINB5) directly related to the death
of PCa cell lines (Table 1).
Table 1 Up- and down-regulated genes and their representing functional groups in PC3-AKR1C3 transfectants
Up-regulated genes Down-regulated genes
Cancer, Cellular growth and proliferation Cell death
BEX1 Brain expressed, X-linked 1 CALB1 Calbindin 1, 28 kDa
FBLN1 Fibulin 1 CD70 CD70 molecule
FGD3 FYVE, RhoGEF and PH domain containing 3 DDIT4 DNA-damage-inducible transcript 4
HBEGF Heparin-binding EGF-like growth factor FAM162A
KLK3 Kallikrein-related peptidase 3 FTH1 Ferritin, heavy polypeptide 1
KLK6 Kallikrein-related peptidase 6 HCLS1 Hematopoietic cell-specific Lyn substrate 1
WNT5B Wingless-type MMTV integration site family, member
5B
ID1 Inhibitor of DNA binding 1, dominant negative helix-loop-helix
protein
IL1RN Interleukin 1 receptor antagonist
LDLR Low density lipoprotein receptor (familial hypercholesterolemia)
NEFL Neurofilament, light polypeptide 68 kDa
PERP PERP, TP53 apoptosis effector
PMAIP1 Phorbol-12-myristate-13-acetate-induced protein 1
PRDM1 PR domain containing 1, with ZNF domain
RUNX2 Runt-related transcription factor 2
SERPINB5 Serpin peptidase inhibitor, clade B (ovalbumin), member 5
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Page 7 of 16IPA also identified the p53 canonical pathway as the
most significant pathway (P < 0.0008) overrepresented by
PERP (TP53 apoptosis effector), PMAIP1 (phorbol-12-
myristate-13-acetate-induced protein 1, induction of apop-
tosis), and SERPINB5 (serpin peptidase inhibitor, clade B,
member 5, aka maspin). In addition, alanine and aspartate
metabolism were the second and third most significantly
overrepresented pathways (P < 0.003), respectively, repre-
sented by DLAT (dihydrolipoamide S-acetyltransferase)
and NARS (asparaginyl-tRNA synthetase). When the list of
153 down-regulated genes identified by the BRB Array-
Tools analysis was filtered by Ingenuity and expressed in
both human and PC-3 cells (Additional file 2), 58 genes
were eligible for forming networks and expressed categori-
zation. The endoplasmic reticulum stress pathway was
identified as the most significant (P < 0.004, ATF, HSPA5).
The p53 pathway along with alanine and aspartate metabo-
lism were also present, but at a less significant level.
Assessment of PC3-AKR1C3 aggressiveness by literature
analysis
Literature analysis predicted pathological development
and progression of PC-3 cells overexpressing AKR1C3.
Analysis of common biological functions of the 70 up-
and 153 down-regulated genes using IRIDESCENT
showed that PSA, b-catenin, ER, and aggressiveness are
the most significant keywords overrepresented among
the up-regulated genes. Those terms characterized acti-
vation of specific biological processes induced by over-
expression of AKR1C3 in PC-3 cells, and were more
specific than general functions identified by IPA. BEX1
and FBLN were associated with ER, while FBLN1,
HBEGF, KLK3, and TMPRSS2 were associated with
tumor aggressiveness (Figure 3A). A strong connection
of WNT5B to the keyword “b-catenin” was also identi-
fied. Significantly, ER was connected to all these genes
directly or indirectly (Figure 3A).
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Figure 2 Activation of the IGF-1 pathway in PC3-AKR1C3 transfectants. (A) Ingenuity analysis identified that activation of the IGF-1 signaling
pathway is statistically significant in PC3-AKR1C3 transfectants. Up-regulated genes, or focus genes, are marked by in filled gray; and uncolored
genes indicate they are expressed in the microarray datasets under any conditions and may participate in signal transduction. Branches of the
IGF-1 pathway that did not have at least one focus gene were not included in the diagram. (B) Western blot analysis of total and
phosphorylated IGF-1R b and Akt in PC3-AKR1C3 stable transfectants. The analysis was performed 3 times; and all experiments showed
consistent elevated phosphorylation of IGF-1R b (Tyr 1131) and Akt (Ser 473) in PC3-AKR1C3 transfectants. Image analysis confirmed that levels of
phosphorylated IGF-1R b and Akt are statistically higher in PC3-AKR1C3 transfectants as compared to PC3-mock transfectants.
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Page 8 of 16More than 400 keywords were identified to be signifi-
cantly overrepresented in the 76 down-regulated genes;
and the majority of them were related to carcinogenic
processes (data not shown). “Tumor suppressor” was
identified as the most significant keyword connecting
the majority of these genes including SERPINB5 and
CHD11 (Figure 3B). “Angiogenesis” was another signifi-
cant keyword connecting many of the down-regulated
genes in PC3-AKR1C3 transfectants (Figure 3B). In
addition, as identified by Ingenuity, PERP and PMAIP1
were strongly related to each other and to “p53 tumor
suppressor” keyword (Figure 3B). Consistently, the
majority of these genes were regulated by 17b-estradiol,
androstenediol, and 5a-DHT as described in Figure 1.
Promoter analysis of up- and down-regulated genes in
PC3-AKR1C3 transfectants
The PAINT analysis predicted whether the differentially
expressed genes between PC3-AKR1C3 and PC3-mock
transfectants are regulated by common transcription fac-
tors. Based on results from PAINT analysis, GATA-1
(aka globin transcription factor 1) was identified as the
major TRE shared by 7 of the 27 up-regulated genes fol-
lowed by less overrepresented CP2, SEBP-1, and USF,
with P < 0.05 (Figure 4A). It should be noted that any
given gene can have more than one TRE within 2 kb of
5’-flanking regions queried by PAINT; and some genes
appeared to share a given TRE. Additional analysis of
the 70 genes from the BRB ArrayTools analysis identi-
fied GATA-1 and SEBP-1 as major TREs shared among
the up-regulated genes in PC3-AKR1C3 transfectants
(data not shown). Among the 76 genes down-regulated
in PC3-AKR1C3 transfectants, ATF, MyoD, E2, and Elk-
1 TREs were found to be major TREs, with P <0 . 0 5
and FDR < 0.3 (Figure 4B). Analysis of all 153 down-
regulated genes in PC3-AKR1C3 transfectants identified
by the BRB ArrayTools analysis showed the same set of
TREs.
VEGF expression in PC3-AKR1C3 transfectants
Elevated AKR1C3 expression promoted VEGF expres-
sion and secretion in PC-3 cells. AKR1C3 had differen-
tial effects on the expression of various VEGF isoforms.
Semi-quantitative RT-PCR analysis of VEGF isoform
mRNA demonstrated that only the mRNA for the
VEGF A isoforms significantly elevated in PC3-AKR1C3
C1 as compared to PC3-mock transfectants from 3
repeats (P < 0.05), whereas there was no difference in
A B
Figure 3 Phenotypic presentation of PC3-AKR1C3 transfectants from literature analysis. Relationships between differentially expressed
genes in PC3-AKR1C3 transfectants and the most significantly overrepresented keywords published with those genes in MEDLINE abstracts and
titles are identified. Genes are circled, keywords are not circled. Thickness of the line correlates with the mutual information between the terms
(thicker lines mean more mutual information). (A) Up-regulated genes that have been documented as related to aggressive carcinomas, PSA, b-
catenin, and ER. (B) Down-regulated genes that are related to angiogenesis, tumor suppression and, more specifically, tumor suppression via p53.
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Page 9 of 16VEGF B, C, or D expression between AKR1C3-positive
and negative transfectants (Figure 5). Both AG1024 and
LY294002 suppressed VEGF A mRNA expression in
PC3-AKR1C3 C1, but had no effects on the expression
of other VEGF isoforms expression. In addition, quanti-
fication of total VEGF proteins secretion showed that
PC3-AKR1C3 C1 produces an average of 3,882.8 pg
VEGF/μg of total protein and is significantly higher than
3,351.8 pg VEGF/μg of total protein secreted by
PC3-mock transfectants from 3 independent repeats
(P < 0.05).
Angiogenetic potential of elevated AKR1C3 expression in
PC-3 cells
PC3-AKR1C3 transfectants promoted higher numbers of
EC tubes on Matrigel as compared to PC3-mock trans-
fectants. In PC-3 cell and HMEC-1 co-cultures on the
Matrigel system, HMEC-1 formed sporadic elongated
capillary like tube structures at 24 hour (Figure 6A), but
began disintegrating from 48 to 72 hour after HMEC-1
addition (data not shown). Comparisons among parental
PC-3 cells, PC3-mock, and PC3-AKR1C3 transfectants
were therefore performed at 24 hours after co-culture.
Parental PC-3 cells and PC3-mock transfectants stimu-
lated similar numbers of capillary-like tubes with 149.7
± 22.0 and 130.8 ± 7.3, respectively. The results were
similar to HMEC-1 cultured on Matrigel alone. In con-
trast, 3 clones of PC3-AKR1C3 transfectants possessed a
significantly higher capability in stimulating HMEC-1
tube formation with 218.0 ± 20.2, 237.4 ± 17.1, and
287.8 ± 36.5 tubes (Figure 6B). AKR1C3-enhanced
HMEC-1 tube formation was also observed in AR-
positive human PCa LNCaP cells. LNCaP-AKR1C3
transfectants exhibited elevated capacity in promoting
HMEC-1 tube formation (289.2 ± 45.9) as compared to
LNCaP-mock transfectants (194.9 ± 26.5) (P < 0.05).
Pre-treatment of PC3-AKR1C3 transfectants with
AG1024 led to significantly reduced numbers of
endothelial capillary-like tubes formed in all 3 clones
(119.7 ± 11.1, 124.8 ± 21.2, and 146.9 ± 19.5) as com-
pared to the clones in the absence of the inhibitor (Fig-
ure 6B). The numbers of EC tube formed were not
statistically different between PC3-AKR1C3 transfectants
treated with the inhibitor and PC3-mock transfectants.
A B
Up-regulated in PC3-AKR1C3 Down-regulated in PC3-AKR1C3
Figure 4 Identification of TREs for differentially regulated genes identified in PC3-AKR1C3 transfectants. (A) TREs shared by genes that
are up-regulated in PC3-AKR1C3 transfectants. (B) TREs shared by genes that are down-regulated in PC3-AKR1C3 transfectants. Red color
indicates significant TREs with P < 0.05 and FDR < 0.3.
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LY294002 reduced the numbers of EC tubes to the
levels observed in parental PC-3 cells and PC3-mock
transfectants (Figure 6B).
Discussion
Consistent with previous reports [19-22], we observed
low levels of AKR1C3 immunoreactivity in normal pro-
static epithelium, whereas a strong immunoreactivity is
observed in low grades and advanced PCa using tissue
arrays. Forced expression of AKR1C3 was established in
human PCa PC-3 and LNCaP cell lines to recapitulate
elevated AKR1C3 expression in cancer tissues and to
study potential pathological activities of this enzyme in
cancerous prostate. Bioinformatics analysis and biologi-
cal characterization suggest that elevated AKR1C3
expression in PCa cells not only promotes cancer cell
growth [23] but also enhances angiogenesis. In addition
to the classical belief that AKR1C3 is responsible for
androgen conversion and regulation of AR trans-activa-
tion, AKR1C3 may also activate 17b-estradiol-mediated
signaling pathways to promote PCa progression.
Differences in the prevalence of AKR1C3 expression
in PCa were noted between tissue sections prepared
from individual patients and from tissue arrays. Using
radical prostatectomy samples, Nakamura et al. reported
77.1% (54/70) [19] and we reported 81.8% (9/11) posi-
tive immunoreactivity [20] in adenocarcinoma. Using
tissue array sections, we showed 33.3% AKR1C3 immu-
noreactivity in prostate adenocarcinoma (data not
shown) and Stanbrough et al.s h o w e d5 . 6 %( 1 / 1 8 )[ 2 1 ] .
In contrast, tissue array samples identified as androgen-
independent PCa showed a higher 57.9% (11/19) immu-
noreactivity for AKR1C3 [21]. Wako et al. also reported
a statistically significant positive correlation between
AKR1C3 immunoreactivity and PCa stages [22]. PCa is
a heterogeneous and multi-focal disease; and the sizes,
locations, and stages of PCa tissues obtained for analysis
can affect interpretations. In addition, we previously
described an uneven distribution of AKR1C3 in adeno-
carcinoma in prostatectomy specimens [20]. Tissue
array slides consist of core biopsies of 1.0 to 1.5 mm in
diameter from paraffin embedded specimens; locations
of the cores obtained for tissue array preparation can
significantly affect immunohistochemical staining
results. The differences in AKR1C3 immunoreactivity
obtained from sections prepared from an individual
patient and tissue arrays might result from the uneven
distribution of AKR1C3 in prostate adenocarcinoma.
Since AKR1C3-mediated lipophilic hormone metabolism
may function through a paracrine signaling, it may not
require all cancer cells to express elevated levels of
AKR1C3 to promote disease progression.
In androgen metabolism, AKR1C3 acts as a 3-ketos-
teroid reductase converting 5a-DHT to 3a-diol [7], and
as a 17-ketosteroid reductase converting Δ
4-dione to
testosterone [14]. In addition to androgen metabolism,
recombinant AKR1C3 inter-converts estrone and 17b-
estradiol [13]. Consistent with AKR1C3-mediated ster-
oid metabolism, bioinformatics analysis confirmed that
genes deregulated in PC3-AKR1C3 transfectants are
related to Δ
4-dione, testosterone, 5a-DHT, and 17b-
estradiol. In contrast to other microarray data showing a
positive correlation between AKR1C3 and FST, FST was
significantly suppressed in PC3-AKR1C3 transfectants.
Ingenuity analysis of interactions between AKR1C3 and
FST shows that they are connected via testosterone and
progesterone. In transfectants, AKR1C3 likely reduces
Δ
4-dione to accumulate testosterone [14], which in turn
decreases FST expression [39]. In addition, FST protein
decreases FST mRNA expression [39], but increases the
secretion of progesterone [40].
The connection from AKR1C3 overexpression to the
p53 signaling suggests possible suppression of tumor
suppressive effects of p53 protein and promotion of
prostate cancer aggressiveness. Three down-regulated
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Figure 5 Levels of VEGF mRNA expression in PC3-AKR1C3
transfectants. Total RNA was isolated from PC3-mock and PC3-
AKR1C3 C1 transfectants as well as from PC3-AKR1C3 C1 clone
treated with either 20 µM AG1024 or 10 µM LY294002. Target VEGF
A, B, C, and D mRNA species were PCR amplified using isofrom-
specific primer pairs. PCR products were separated by 1% agarose
gel electrophoresis; and images of ethidium bromide-stained gels
were acquired.
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Page 11 of 16genes, SERPIN5B, PERP and PMAIP1, have been identi-
fied as exclusive members of the p53 pathway, which is
further highlighted by their connections to the “p53
tumor suppressor” keyword. Expression of the p53 gene
is not detectable in PC3-mock transfectants but is
detectable in AKR1C3 transfectants, albeit at a very low
level. This may be due to the fact that PC-3 cells are
hemizygous for chromosome 17p [41]; and a base pair
deletion of the single copy of the p53 gene which gener-
ates a frame shift and a new in-frame stop codon may
not provide the optimal hybridization between wild-type
p53 probes and p53 transcripts in PC-3 cells. SERPIN5B
has been identified as a suppressor of angiogenesis [42];
and down-regulation of this gene in PC3-AKR1C3 trans-
fectants suggests the role of AKR1C3 in promoting
blood vessel formation. PERP [43] and PMAIP1 [44] are
parts of the p53 signaling branch leading to apoptosis;
and suppressed expression of these genes suggests that
AKR1C3 may also promote cancer progression through
apoptosis evasion. Other members of the apoptotic
branch, such as FAS and Caspase 6, were also down-
regulated in PC3-AKR1C3 transfectants, although their
changes did not pass our strict statistical criteria.
A summary of these findings are presented in Additional
file 3.
The advantage of using a literature-based analysis over
a GO enrichment analysis is that it permits commonal-
ities to be identified between genes and their associated
diseases, phenotypes, metabolites and chemical com-
pounds and is complementary to GO categories. This
approach greatly expands the number and nature of
commonalities that can be identified and has been used
in other microarray studies [45,46]. The downside is
that associations are probabilistic, which tends to be
more problematic when two terms have only been co-
mentioned a few times, whereas in GO they are manu-
ally corrected and have a lower false-positive rate.
A search for biological or pathological functions of the
up- and down-regulated genes in PC3-AKR1C3 trans-
fectants with literature keywords refined and confirmed
Ingenuity’s findings. “Aggressiveness” is the most signifi-
cant process represented by the up-regulated genes in
PC3-AKR1C3 transfectants, and directly relates to other
keywords: “PSA”, “b-catenin” and “ER”.H B E G Fi d e n t i -
fied as one of EGF receptor ligands is strongly asso-
ciated with large tumor size, high histoprognostic
grading, and aggressiveness of breast cancer [47].
FBLN1, a calcium-binding, acidic glycoprotein of extra-
cellular matrix, is positively correlated with ovarian can-
cer progression [48]; and elevated expression of KLK3
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Figure 6 Angiogenic properties of PC-3 cells overexpressing AKR1C3 on Matrigel. (A) PC-3 cell-mediated HMEC-1 tube formation was
performed in a co-culture system on Matrigel basement membrane matrix. Formation of HMEC-1 tubes was imaged at 24 hours after HMEC-1
co-culture with either PC3-mock or PC3-AKR1C3 transfectants. (B) Quantification of HMEC-1 tube formation. The number of EC tubes were
counted; and results were compared between PC3-mock and PC3-AKR1C3 transfectants and presented as mean ± SEM from 12 experiments for
the 4 independent clones. The number of HMEC-1 tubes formed were also determined by pre-treating PC-3 transfectants with 20 µM AG1042 or
10 µM LY294002; and results were presented as mean ± SEM from at least 3 independent assays. * indicates P < 0.05 between PC3-mock and
PC3-AKR1C3 transfectants.
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Page 12 of 16and TMPRSS2 have been associated with PCa aggres-
siveness [49]. In the “CTNNB” (or b-catenin) keyword,
both WNT5B (a representative Wnt family protein) and
b-catenin are well-known pathways in carcinogenesis;
and elevated expression of these molecules have been
associated with AR, ER, and cancer progression [50,51].
In the “ER” keyword, HBEGF [52], FBLN1 [53], BEX1
[54], and TMPRSS2 [55] are regulated by 17b-estradiol
through the ER. The up-regulated genes indentified in
PC3-AKR1C3 transfectants surrounding these 4 key-
words are interconnected and associated with more
aggressive cancer phenotypes.
T h em a j o r i t yo fd o w n - r e g u l a t e dg e n e si nP C 3 -
AKR1C3 transfectants have been identified as tumor or
angiogenesis suppressors. The keyword “tumor suppres-
sor” is the most predominant among genes down-regu-
lated in PC3-AKR1C3 transfectants. Reduced expression
of tumor suppressors is associated with development
and progression of malignancies. For example, SER-
PINB5 inhibits cell invasion, as well as angiogenesis and
promotes apoptosis [56]. Genetic loss of the stress
response DDIT4 (or REDD1) gene promotes anchorage-
independent cell growth and elicits tumorigenesis in a
mouse model [57]. Similarly, loss of CDH11 tumor sup-
pressor gene shows the highest frequency in retinoblas-
toma tumors [58]. Genes related to “angiogenesis”
keyword are predominantly negative regulators of angio-
genesis, suggesting the activation of angiogenic pro-
cesses in PC3-AKR1C3 transfectants. For instance, the
RUNX2 transcription factor is negatively correlated to
angiogenesis [59]. Overexpression of FST (an inhibitor
of activin) in human small cell lung cancer cells sup-
presses metastatic colonies and microvessel density in
SCID mice [60]. “Angiogenesis” and “tumor suppressor”
keywords are interconnected by the down-regulated
genes identified in PC3-AKR1C3 transfectants.
Several TREs identified among up- ad down-regulated
genes in PC3-AKR1C3 transfectants are also related to
steroid metabolism. Steroid hormones such as proges-
terone up-regulates GATA-1 expression [61]; and mem-
bers of the GATA transcription factor family (GATA-2
and GATA-3) are involved in the androgen regulated
PSA expression [62]. CP2 implicated in the control of
mRNA turnover and translation is involved in post-
transcriptional regulation of AR expression [63].
SREBP-1 (sterol regulatory element binding protein-1)
interacts with a 17b-estradiol and insulin-sensitive SRE-
1 cis-element [64]; and up-regulation of SREBP-1 is
associated with androgen-independent PCa progression
[65]. USF1 (upstream stimulatory factor 1) has been
shown to act cooperatively with SREBP-1 in sterol bio-
synthesis [66]. Many of the down-regulated genes
shared MyoD or Elk-1 TRE. MyoD (myoblast determi-
nation protein 1) is a new component of the ERa
complex [67]. Elk-1 (an ETS-related gene whose activa-
tion is regulated by 17b-estradiol [68]) plays a role in
prostate cell proliferation [69].
Although the involvement of AR in tumor angiogen-
esis of PCa remains unsettled, several reports have sug-
gested that angiogenesis can be independent of the AR.
For example, expression of interleukin (IL)-8 activates
androgen-independent growth and angiogenesis in
LNCaP cells [70]. Consistent with our results identifying
ER trans-activation in AKR1C3-positive PC-3 cells, a
variety of estrogenic, anti-estrogenic, and selective ER
modulator (SERM) compounds has been suggested to
have chemopreventive or therapeutic utilities for PCa
reviewed by Ho [71]. In addition to trans-activation of
t h eE Rb y1 7 b-estraldiol, 5a-androstane-3b,1 7 b-diol
(3b-diol, an androgen metabolite formed by 3b-HSD
activity of AKR1C3 [72]), has been shown to be capable
of trans-activating ERb and regulating PC-3 cell growth
in cultures and in xenografts in nude mice [73]. Roles of
AKR1C3-mediated AR and ER trans-activation in PCa
progression require further study.
More than a dozen different proteins have been iden-
tified as angiogenic factors, meaning that they are
released by tumors as signals for angiogenesis. These
factors include acidic fibroblast growth factor (FGF),
basic FGF, angiogenis, epidermal growth factor (EGF),
granulocyte colony-stimulating factor (GM-CSF), hepa-
tocyte growth factor (HGF), IL-8, placental growth fac-
tor (PGF), platelet-derived growth factor (PDGF), scatter
factor, transforming growth factor (TGF)-a,t u m o r
necrosis factor (TNF)-a,a n dV E G F .A m o n gt h e s e
angiogenic factors, VEGF is one of the most important
factors, and is a main target of many anti-angiogenic
agents. Although elevated VEGF expression in PC3-
AKR1C3 transfectants suggests that VEGF might be
responsible for promoting EC tube formation in the in
vitro angiogenesis model, our results did not rule out
the involvement of other angiogenic factors in promot-
ing AKR1C3-positive cell-mediated angiogenesis. In
addition, mechanisms of the secreted VEGF from PC3-
AKR1C3 transfectants in activating VEGF receptors in
ECs with subsequent capillary-like tube formation will
need to be studied.
Although the role for estrogen in PCa progression
remains controversial, our results might provide a
mechanistic explanation for why a combination of 3a-
diol and 17b-estradiol administration promotes prostatic
epithelial hyperplasia in castrated beagle dogs mimicking
human PCa [74]. 17b-estradiol can activate IGF-1 sig-
naling pathway in human PCa [75]. IGF-1 [76] and Akt
[77], well-known players in promoting PCa progression,
are identified as results of elevated AKR1C3 expression
in PC-3 cells. AKR1C3, therefore, can be positioned as a
critical regulatory molecule in activating/inactivating
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signaling pathways. AKR1C3 can also be described as a
molecule that provides a survival mechanism to promote
angiogenesis in cancer progression. Based on this com-
munication, inter-relationships among AKR1C3, ER,
IGF-1, Akt, and subsequent VEGF expression deserve
further investigation for tumor angiogenesis and
progression.
Conclusions
Elevated expression of AKR1C3 has been identified and
confirmed in some cases of localized and advanced
prostate adenocarcinoma. Bioinformatics data and biolo-
gical characterization demonstrate that elevated
AKR1C3 expression in PCa cells can promote cancer
cell growth and cancer cell-mediated angiogenesis. Our
results strongly suggest AKR1C3-mediated steroid hor-
mones metabolism may activate growth factor IGF-1
and cytoplasmic Akt signaling pathways as well as
VEGF expression. AKR1C3 might be placed upstream of
the well known growth factor receptor signaling and
angiogenesis pathways for promoting PCa progression.
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Additional file 1: List of genes up-regulated in ACR1C3
transfectants. 27 overlapping genes from both analyses presented first,
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Additional file 2: List of genes down-regulated in ACR1C3
transfectants. 76 overlapping genes from both analyses presented first,
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unique genes from BRB ArrayTools analysis. Bold and italicized were 58
genes expressed in Human and in PC-3 cells.
Additional file 3: Parts of p53 signaling disturbed in PC-ACR1C3
transfectants. Red/green shading indicates up- and down-regulated
genes, respectively. Grey shading highlights non-changing genes. White
shading indicates no information available about expression of these
genes.
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